MedTrace Logo

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

NCT02781480 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-07-12

Study results available
· View outcomes & findings →

Summary

A clinical trial of AAV2/5 vector for patients with Defects in RPE65

Conditions

  • Leber Congenital Amaurosis

Interventions

BIOLOGICAL

AAV RPE65

Comparison of different dosages of AAV RPE65

Sponsors & Collaborators

  • MeiraGTx UK II Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-12-31
Completion
2018-12-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02781480 on ClinicalTrials.gov